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ABSTRACT

A systematic review of the available studies on the interference of OmoMyc with Myc’s
function in cancerous cells is presented. Myc is a transcription factor that regulates
cellular processes such as apoptosis, proliferation, and differentiation. However, Myc is
often overexpressed in a variety of cancers, resulting in abnormal growth of cancer cells.
Although the inhibition of Myc has been highly desired, it remains a challenge due to its
undruggable characteristics. Attempts to inhibit Myc have involved the usage of
small-molecules, but these attempts have failed, causing adverse effects and incomplete
inhibition of Myc. Despite promising preclinical studies of OmoMyc, it is only
considered as a proof of principle due to the difficulties to deliver into cells. The results
of this systematic review are discussed in hopes of overcoming difficulties in the delivery
of OmoMyc in vitro t ranscribed mRNA (IVT-mRNA) in efforts to inhibit the
overexpression of Myc.
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INTRODUCTION

With 1.7 million new cases and 0.6 million deaths in the last year, cancer has become one
of the most devastating causes of death in the United States (Siegel et al. 2019). From the
efforts to understand its cause, we now know that cancer occurs due to changes in our
genes. These cancer-causing genes are termed oncogenes. Myc is one of the major
proto-oncogenes, which makes it a desirable target for cancer treatment. In normal cells,
Myc is responsible for the regulation of various target genes that work together in the
transcription process and cell proliferation. In combination with Myc’s partner protein,
Max, the activation and repression of many target genes are regulated (Kalkat et al.
2017). The Myc/Max complex is composed of bHLH-Zip DNA binding proteins which
recognizes the E-box sequences in DNA to activate transcription (Cascon et al. 2012,
Valovka et al. 2013). However, the expression of Myc is often amplified in many types of
cancers. This amplification results in increased Myc RNA expression, leading to cancer
cell proliferation, tumor growth, and angiogenesis, among other cellular processes. These
are the primary characteristics of cancers.

Previous attempts to inhibit Myc have failed. The main reason for difficulties targeting
Myc is due to its structure, Myc’s role in healthy cells, and Myc’s location in the cell.
Due to Myc’s structure, researchers have had difficulties in finding sites that are
commonly used by pharmacological strategies. Since Myc is found in healthy cells,
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utilizing small molecules results in a high risk of side effects on the healthy cells. In
addition, Myc is located in the nucleus, making it difficult for access by small molecules
and antibodies.

The discovery of OmoMyc has aided efforts in finding an efficient solution. OmoMyc is
a dominant-negative form of Myc, differing in four amino acids, E57T, E64I, R70Q, and
R71N (Soucek et al. 1998). The four changes altered the transcriptional effects of Myc by
competitive inhibition. The competitive inhibition interferes with the heterodimerization
of Myc/Max, which alters the function of Myc (Sauvino et al. 2011). OmoMyc also
prevents the binding of Myc/MAX complex to promoter E-boxes, which inactivates
Myc-derived transcriptions.

Preclinical studies have shown that OmoMyc is successful in the inhibition of Myc in
transgenic mouse models. In these mouse models, OmoMyc inhibited Myc resulting in
tumor growth inhibition and eradication (Soucek et al. 2008). These models showed mild,
reversible side effects, validating the safety of OmoMyc. Yet, clinical transition of
OmoMyc remains a challenge because firstly, OmoMyc is too big to cross the cell
membrane. Secondly, in physiological conditions, due to proteinase in plasma, proteins
can be degraded. Thirdly, proteins can be immunogenic. For these reasons, OmoMyc is
only considered as proof of principle.
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Recent studies have examined the effects of anchoring small peptides that are known to
assist the cellular entry of OmoMyc. However, this approach still requires the
administration of the OmoMyc protein in a large amount due to limited delivery
efficiency. The degradation of OmoMyc and its potential immunogenicity still remains.
We examined that the delivery of OmoMyc in a form of in vitro t ranscribed (IVT)
mRNA would enhance the intracellular delivery of OmoMyc protein, therefore, resulting
in a greater inhibition of Myc. Considering that one mRNA molecule produces multiple
proteins, this strategy would inhibit Myc more efficiently than delivery of OmoMyc
protein. In order to protect and deliver OmoMyc mRNA, lipid-based nanoparticles, which
are clinically relevant delivery vectors, will be examined. Using lipid-based nanoparticles
as a vector for mRNA delivery reduces the risks of degradation and immunogenicity in
plasma. We anticipate to demonstrate the viability of OmoMyc in lipid-based mRNA
therapy for the future of cancer therapeutics.
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METHODS

Sample of Studies
A systematic review of studies available by 2008 from biomedical journals such as Cell,
Nature, and Science Translational Medicine a re conducted. From this, we propose to
examine the intracellular delivery of OmoMyc IVT-mRNA using lipid-based
nanoparticles, and the Myc inhibition by translated proteins in cancer cells
overexpressing Myc. Keywords, OmoMyc, Myc, cancer therapeutics, in vitro transcribed
(IVT) mRNA, mRNA therapy, lipid-based nanoparticles, and cancer therapeutics were
used on these computerized databases. Since researchers often use the terms, vectors and
delivery vectors, we conducted searches using these substitute terms as well.

After identifying the main body of reports, we examined the references of these reports to
obtain other relevant reviews that were not included in our initial database search. From
these reports, we examined the journal volumes that they were in.

Studies that tested the delivery and effect of OmoMyc on any type of mouse models or
xenograft models will be included. Relevant articles were extracted from several online
databases using predefined data fields, indicating the year of the study, the topic of the
study, and the effectiveness of the study.
Selection Criteria
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We used the following criteria to select studies for inclusion in the systematic review.
1. We only included studies whose main focus involved Myc as a therapeutic target.
Thus, we excluded studies in which Myc only played a minor role or was briefly
mentioned.
2. We included studies who mentioned the three Myc gene family members, MYC,
MYCN, and MYCL. These three families are linked to Myc inhibitory strategies.
3. We only included studies published by 2008, as technology, cancer therapeutics
mechanisms, and knowledge of Myc’s properties rapidly change over time.
4. We included studies who delivered OmoMyc, and/or expressed OmoMyc in
cancerous cells, and/or tested the efficacy of OmoMyc.
5. We included studies that used Polymerase Chain Reactions (PCR) and Western
Blot analysis.
6. We included studies who delivered OmoMyc in protein form or in mRNA form.
7. We included studies in peer-reviewed journals and notable academic articles in
our search.
Our selection criteria led to a database containing 128 studies involving the delivery and
efficacy of OmoMyc in its protein form and in its mRNA form. Of the 128 studies, 100
were peer reviewed journals. The 128 studies consisted of 117 articles, 6 dissertations
and theses, 3 newspaper articles, and 2 reviews. The main keywords that were shown in
the articles were proto-oncogene proteins, cancer, Myc protein, gene expression,
transcription factors, and cell proliferation.
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DATA

Selected Studies
Of the resulting database, we selected five studies discussing Myc inhibition, OmoMyc
functions, and the utilization of lipid encapsulation for the delivery of OmoMyc.

I. MYC INHIBITION

Myc is a basic helix-loop-helix leucine zipper transcription factor that regulates
the expression of the intracellular and extracellular processes that are necessary
for growth of somatic cells (Soucek et al. 2008). Due to this, the inhibition of Myc
is one of the main pharmacological approaches in cancer therapeutics. Despite the
potential success of inhibiting Myc, there are detrimental side effects that would
inhibit the proliferation of normal tissues (Soucek et al. 2008).

When genetically modelling the therapeutic impact and the side effects of Myc
inhibition in a preclinical mouse model of Ras-induced lung adenocarcinomas,
studies have shown that inhibition of Myc has various detrimental side effects.
However, these effects are reversible and tolerable. Complete inhibition of Myc
would have negative effects on tissues such as the gastrointestinal tract, skin, and
bone marrow (Soucek et al. 2008). Challenges such as the irreversible side effects
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on healthy somatic cells have led to concerns about Myc inhibition as a way to
treat cancer.

In the Soucek study, Omomyc was conditionally expressed using the
cytomegalovirus (CMV) early promoter. CMV is associated with high levels of
expression in multiple tissue types (Soucek et al. 2008). The coding sequence for
OmoMyc was placed downstream of a tetracycline-responsive promoter element
(TRE). Mouse models were utilized in this study as well. Mice with the
TRE-Omomyc transgene were then crossed. From there, a polymerase chain
reaction with reverse transcription (RT-PCR) ensured that OmoMyc expression
was in the tested tissues.

To assess the inhibition of Myc’s function using OmoMyc, the study used a lung
cancer mouse model, where tumorigenesis is initiated by activation of
endogenous Kras. Kras are common mutations in human non-small-cell lung
cancers (Soucek et al. 2008). To analyze the contribution of endogenous Myc,
TRE-OmoMyc was crossed. CMVrtTA mice and OmoMyc induced were
maintained for four weeks. Lesions were absent from all mice expressing
KrasG12D and OmoMyc. As a result, the expression of OmoMyc suppressed the
fraction of cell proliferation. Apoptosis in the residual lesions of mice expressing
Omomyc was observed. At the end of the study, the lung morphology, cell
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proliferation, and apoptosis of the mice were assessed immunohistochemically.
The mice expressing KrasG12D without OmoMyc developed multiple
hyperplasias (Soucek et al. 2008). This study suggested that endogenous Myc is
required to maintain the survival of KrasG12D induced lung tumors. This study
confirmed that Myc has a crucial role in proliferation of healthy and cancerous
cells, reiterating that Myc’s inhibition would cause adverse side effects. Inhibition
of Myc led to shrinkage of lesions, reduction of lesion multiplicity, significant
apoptosis in residual lesions, and reduction of proliferating cells (Soucek et al.
2008). Another trial in the study showed that Myc inhibition induced no apoptosis
and that OmoMyc expression was not harmful to the mice. As a whole, the study
showed that Myc inhibition showed rapid regression of both incipient and
established lung tumors, and affects normal regenerating tissues (Soucek et al.
2008). The study showed that OmoMyc could be a potential Myc inhibitor.

Summary of the Findings of the Soucek Study
1. Myc inhibition prompts rapid regression of incipient and
established lung tumors. This indicates endogenous Myc’s role in
the maintenance of Ras-dependent tumors in vivo (Soucek et al.
2008).
2. Systemic Myc inhibition has effects on normal generating tissue
(Soucek et al. 2008). This again emphasizes the side effects of
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Myc inhibition and why OmoMyc is currently considered as a
proof principle. These side effects may be reversible, but there is
still some uncertainty in OmoMyc’s efficacy in the inhibition of
Myc.
3. OmoMyc has potential to be a way to inhibit Myc’s function in
cancerous cells.

II. TESTING THE EFFICACY OF OMOMYC

OmoMyc has been highly sought after in the inhibition of Myc. Current studies
have shown that OmoMyc is a highly stable homodimer and forms a tight
protein/DNA complex (Jung et al. 2017). Knowing this aids in efforts to
understand OmoMyc gene expression regulation. Studies have observed the
expression of OmoMyc and have purified the OmoMyc recombinant protein. It is
also observed that when binding to the DNA, it forms a scissor-like structure at
the E-box. This is done with stabilization through the phosphate-backbone
interactions with DNA.

In the Jung study, the protein/DNA complex of OmoMyc was compared to the
Myc/Max DNA complex, indicating that the basic region of both complexes have
the same contacts to DNA. This suggests that OmoMyc has the capabilities of
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competing with the Myc/Max complex for E-box binding (Jung et al. 2017).
Other OmoMyc functionalities examined by this study includes attenuation of
oncogenic Myc-dependent gene expression and suppression of tumor growth.
This study focuses on the reproduction of OmoMyc’s efficacy with small
molecule inhibitors and the analysis of OmoMyc’s target genes in vivo. Through
expression and purification of recombinant OmoMyc, and Myc and Max protein,
crystallization of OmoMyc, and assays, “findings suggest that individual genes
encoding rate-limiting proteins involved in basic cell biological processes respond
to the difference between physiological and supra-physiological MYC levels and
that OmoMyc specifically inhibits tumor cell growth as it suppresses expression
of this group of genes” (Jung et al. 2017).

Summary of the Findings of the Jung Study
1. OmoMyc is a highly stable homodimer and forms a tight
protein/DNA complex (Jung et al. 2017). Tight protein/DNA
interactions are favorable.
2. OmoMyc blunts promoter invasion by oncogenic Myc levels (Jung
et al. 2017). This reduces the gene expression of Myc-dependent
tumors.
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On a similar basis to the Jung study, a 2011 study by Savino indicated that
OmoMyc selectively targets the Myc interactome, affects the transactivation and
repression by influencing Myc binding to target gene promoters, and affects
proliferation and survival of cells in culture. OmoMyc prevents Myc binding to
promoter E-boxes. This study utilized Western Blot analysis, immunoblotting,
and mouse models. Indication that OmoMyc selectively targets the Myc
interactome was shown by immunoprecipitations on cells expressing Myc. The
Myc interactome consists of interaction with the bHLHZip protein Max. This
interaction is crucial to Myc’s function.

In efforts to investigate OmoMyc effects in gene regulation, luciferase reporter
and chromatin immunoprecipitation (ChIP) assays were conducted on two genes
encoding the nucleolar protein nucleolin and the cyclin-dependent kinase inhibitor
p21. These represent the “direct targets of Myc mediated activation and
repression” (Sauvino et. al 2011).

Summary of the Findings of the Savino Study
1. OmoMyc selectively targets the Myc interactome (Savino et al.
2011). Selective targeting increases the effectiveness and
efficiency of drug delivery.
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2. OmoMyc differentially affects transactivation and repression by its
interaction with the Myc/Max complex. OmoMyc affects Myc
binding to target gene promoters (Savino et al. 2011).
3. OmoMyc influences proliferation and cell survival in culture
(Savino et al. 2011).

The third study retrieved from the database also utilized immunoprecipitations,
Western blotting, and mouse models to observe the efficacy and mechanisms of
OmoMyc in the inhibition of the Myc oncogene. The study shows that treating
cells with recombinant OmoMyc leads to a reduction in the levels of the Myc
protein (Demma et al. 2019). Proximity ligation assays (PLAs) have shown that
OmoMyc can interact with the Myc complex. This interaction is the formation of
dimers with both Max and differentially labeled OmoMyc monomers in the cell
(Demma et al. 2019). Translation of ribosome affinity purification (TRAP) and
RNA immunoprecipitation (RIP) experiments suggest that Myc, OmoMyc , and
Max can interact with ribosomes and Max RNA in conditions where ribosomes
are intact. This is an indication of cotranslational dimerization of proteins with
Max (Demma et al. 2019).

The Demma study shows that recombinant OmoMyc inhibits cancer cell
proliferation and affects MYC-mediated transcriptions (Demma et al. 2019). After
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purification, recombinant OmoMyc was used to treat cell lines where Myc was
amplified or stabilized. Effects on lymphoma cell lines containing high levels of
Myc have shown sensitivity to OmoMyc. In contrast, lymphoma cell lines
containing low levels of Myc are insensitive to OmoMyc.

In addition to demonstrating how OmoMyc inhibits cancer cell proliferation, the
study discussed how OmoMyc binds to the Myc/Max complex. They utilized a
biotinylated OmoMyc to immunoprecipitate Myc and Max from cells. After
treatment with two different amounts of OmoMyc, 2.5 μM or 10 μM, the cells
were then lysed and immunoprecipitation with anti-Myc, anti-Myc, and
streptavidin were carried out. Western blotting was used to show that when the
cells were treated with OmoMyc, a reduction in the amount of Myc that could be
immunoprecipitated with Max occured (Demma et al. 2019). Myc and Max were
bound to biotinylated OmoMyc. This showed successful interaction of OmoMyc
with Myc and Max in cells and the effect of OmoMyc on Myc stability and
protein levels. OmoMyc was also observed to have directly targeted and localized
to the nucleolus in cells. Most importantly, OmoMyc decreased the overall level
of Myc in the cell.
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Summary of the Findings of the Demma Study
1. Recombinant OmoMyc inhibits cancer cell proliferation and
affects Myc-mediated transcription (Demma et al. 2019).
2. OmoMyc interacts with the Myc/Max complex and leads to the
destabilization of Myc (Demma et al. 2019).
a. OmoMyc forms heterodimers with Max in the cells, which
bind to promoter regions of Myc target genes (Demma et
al. 2019). This shows OmoMyc’s success in its interactions
with Myc.
3. OmoMyc binds to E-box sequences in DNA and displaces
Myc/Max heterodimers (Demma et al. 2019).
4. OmoMyc localizes to the nucleolus in cells (Demma et al. 2019).
This is especially important in the inhibition of Myc, as Myc is
located in the nucleus of cells, making it challenging to get to.
5. In vivo, OmoMyc rapidly distributes to tissues (Demma et al.
2019). This is promising in developing OmoMyc as a method in
cancer therapeutics.
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III. DELIVERY OF OMOMYC USING LIPID ENCAPSULATION

As shown in the mentioned studies, OmoMyc is a viable option for inhibiting
Myc’s functions, however, due to side efforts of Myc’s inhibitions, OmoMyc is
only considered as a proof of concept. Current delivery methods include small
molecules, which have not been as successful as researchers hoped. In efforts to
understand and develop OmoMyc, we propose to deliver OmoMyc through lipid
encapsulation.

One of the main issues with OmoMyc delivery as a protein is that it is bulky and
has been difficult to pass through the cell membrane to get to the nucleus, where
Myc is located.

The Myc family consists of three related human genes: c-Myc, l-Myc, and n-Myc.
The c-Myc transcription factor is dependent on the heterodimerization with Max
to control target gene transcription (Pan et al. 2015). Current efforts with
small-molecule inhibitors of c-Myc/Max have shown low potency and poor water
solubility (Pan et al. 2015). Due to this, these small-molecule inhibitors are
unsuitable for in vivo. Proposed is a new lipid-based strategy for delivering
oncogenic c-Myc inhibitors for targeting in melanoma cells (Pan et al. 2015).
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An Sn-2 lipase-labile Myc inhibitor prodrug was synthesized and was included in
two αv β3-targeted nanoparticle platforms at 20 and 200 nm (Pan et al. 2015). The
antiproliferate potency was compared to the lipid-free compound (Pan et al.
2015). Human and mouse melanoma cell lines were observed. The data collected
from this study demonstrated a successful nanodelivery of c-Myc inhibitors
through lipid-based encapsulation, suggesting their potential to prevent
melanoma.

This study suggests that delivery through lipid-based encapsulation could be
useful in delivering different Myc targeting therapies. As mentioned previously,
lipid based nanoparticles as a vector for mRNA delivery reduced the risk of
degradation and immunogenicity of OmoMyc in plasma.
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CONCLUSION AND FUTURE WORK

Based on the findings of this systematic review, OmoMyc has the potential to be a viable
option for the inhibition of Myc. The inhibition of Myc has adverse side effects, however,
better understanding of Myc’s functions could lead to a successful development of
OmoMyc. For future studies, we hope to be able to test the efficacy of OmoMyc by
examining the intracellular delivery of OmoMyc IVT-mRNA using lipid-based
nanoparticles. To aid in these efforts, we hope to better understand the Myc inhibition by
translated proteins in cancer cells overexpressing Myc.

Branching from this study, we have designed a research plan in hopes of facilitating the
development of OmoMyc. The first part of the research plan consists of the synthesis of
Omomyc IVT-mRNA. We will subclone the sequence of Omomyc into plasmid DNA,
and amplify the engineered plasmid in E. coli. Afterward, the amplified plasmid will be
purified, and prepared for the in-vitro transcription. Once we have obtained IVT-mRNA,
we will encapsulate it in lipid-based nanoparticles. The second part of the research plan is
to deliver the OmoMyc IVT-mRNA into the cell, which will be translated into protein,
reaching the nucleus to perform its activities. We will be screening different cancer cell
types that are overexpressing Myc to identify the best candidate for the proposed
research. Once we identify the desired cancer cell type, we can deliver the OmoMyc
IVT-mRNA and observe its activities.
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To analyze these activities, Western blot analysis and fluorescent microscopy will be
conducted. We anticipate that this new delivery strategy will help prove the feasibility of
OmoMyc for the treatment of Myc-driven cancers.
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